Clinical therapeutics for phenylketonuria

Drug Delivery and Translational Research
Jaspreet Singh KochharLifeng Kang

Abstract

Phenylketonuria was amongst the first of the metabolic disorders to be characterised, exhibiting an inborn error in phenylalanine metabolism due to a functional deficit of the enzyme phenylalanine hydroxylase. It affects around 700,000 people around the globe. Mutations in the gene coding for hepatic phenylalanine hydroxylase cause this deficiency resulting in elevated plasma phenylalanine concentrations, leading to cognitive impairment, neuromotor disorders and related behavioural symptoms. Inception of low phenylalanine diet in the 1950s marked a revolution in the management of phenylketonuria and has since been a vital element of all therapeutic regimens. However, compliance to dietary therapy has been found difficult and newer supplement approaches are being examined. The current development of gene therapy and enzyme replacement therapeutics may offer promising alternatives for the management of phenylketonuria. This review outlines the pathological basis of phenylketonuria, various treatment regimes, their associated challenges and the future prospects of each approach. Briefly, novel drug delivery systems which can potentially deliver therapeutic strategies in phenylketonuria have been discussed.

References

Jan 1, 1978·Journal of Inherited Metabolic Disease·D M DanksF Rey
Jan 1, 1992·Somatic Cell and Molecular Genetics·T J LiuS L Woo
Mar 1, 1992·Applied Microbiology and Biotechnology·H Orum, O F Rasmussen
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N W BartonR O Brady
May 1, 1990·Archives of Disease in Childhood·I SmithA E Ades
Nov 1, 1974·Archives of Disease in Childhood·M E BlaskovicsS Hack
Jan 1, 1983·Advances in Human Genetics·S Kaufman
Feb 1, 1980·Experimental Neurology·D A Figlewicz, M J Druse
Jul 29, 1993·The New England Journal of Medicine·P VajroO Bernard
Mar 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·R J CristianoS L Woo
Jan 1, 1995·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·S Safos, T M Chang
Jul 1, 1996·European Journal of Pediatrics·F Cockburn, B J Clark
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·C N SarkissianC R Scriver
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·S Kaufman
Sep 15, 1999·The Journal of Pediatrics·S KureK Narisawa
Dec 29, 1999·Human Mutation·C R ScriverP M Nowacki
Apr 18, 2000·Molecular Genetics and Metabolism·C N SarkissianC R Scriver
Sep 26, 2000·Molecular Genetics and Metabolism·R KochF de la Cruz
Oct 24, 2000·European Journal of Pediatrics·S Schweitzer-Krantz, P Burgard
Oct 24, 2000·European Journal of Pediatrics·R Surtees, N Blau
Oct 24, 2000·European Journal of Pediatrics·A MacDonald
Jul 7, 2001·The New England Journal of Medicine·C M EngUNKNOWN International Collaborative Fabry Disease Study Group
Oct 11, 2001·Journal of Pediatric Gastroenterology and Nutrition·P B AcostaJ Breck
Sep 14, 2002·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·Jingzhong LiuYan Zhou
Dec 27, 2002·The New England Journal of Medicine·Ania C MuntauAdelbert A Roscher
Mar 4, 2003·Nature Reviews. Drug Discovery·J Milton Harris, Robert B Chess

❮ Previous
Next ❯

Citations

Apr 6, 2013·Current Opinion in Chemical Biology·Matthew M HeberlingDick B Janssen
Jul 19, 2020·International Journal of Molecular Sciences·Neha SarodayaSuresh Ramakrishna

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.